NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ripple Therapeutics

Ripple Therapeutics

Private
Toronto, OntarioHealthcare & Life Scienceshttps://www.rippletherapeutics.com/

Last Round

Grant

Apr 27, 2022

Total Funding Raised

$12.38M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Ripple Therapeutics is a clinical-stage ophthalmic therapeutics company developing a drug delivery system for controllable, sustained drug delivery without the use of polymers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

sustained-release drug deliverydrug delivery implantophthalmic drug deliverypolymer-free implantlong-acting implantbiodegradable implantdrug eluting implantintravitreal implantglaucoma treatmentretinal disease treatmentbiopharmaceutical partnershipintracameral implantDiabetic Macular EdemaDMERetinal Vein OcclusionRVO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ripple Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Ripple Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ripple Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 27, 2022
GrantFeb 5, 2021
Series ADec 10, 2020

Key People

Founding team and executive leadership

Tom Reeves

President & CEO

Executive Team

Wendy Naimark

Chief Technology Officer

Executive Team

Ripple Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Monthly visitors increased 39% MoM.

  • Jan 8, 2026

    Monthly visitors increased 39% to 2.5K.

Ripple Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ripple Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ripple Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersToronto, Ontario
Employee Range43
Year Founded2020
Last FundingApr 27, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.